Found 110 clinical trials
Physical Rehabilitation Evaluation and Optimal Physical Therapy (PRE-OPT)
(n=200) Phase 2: This is a randomized controlled trial to 1) quantify the effects of (i) physical therapy compared to (ii) a control group in individuals with AWS following breast cancer surgery related to physical activity and physical impairments such as lymphedema, shoulder motion, function, and pain (n=44, 22 in …
- 0 views
- 19 Feb, 2024
Clinician Communication About Sexual Health
The objective of this study is to adapt a previously tested brief intervention aimed at enhancing clinicians communication about sexual health (iSHARE) to a mobile web-based platform showcasing a two-part podcast and to assess the feasibility, acceptability, and preliminary effects of the intervention in breast cancer clinicians.
- 0 views
- 19 Feb, 2024
Vacuum Assisted Biopsy Immediately Before Surgery as an Intra- or Pre-Operative Surrogate for Patient Response to Neoadjuvant Chemotherapy for Breast Cancer
Neoadjuvant chemotherapy (NAC) is common practice in the primary treatment of breast cancer, leading to a complete pathologic remission (pCR) of the tumor in more than 50% in aggressive tumor types. As NAC induces different response patterns, radiologic imaging is not sufficiently accurate in predicting residual disease.
- 0 views
- 19 Feb, 2024
Improving Uptake of Genetic Cancer Risk Assessment in African American Women- Video
Genetic counseling and testing (GCT) provides invaluable information for women who are at-risk of hereditary breast and/or ovarian cancer (HBOC). Black women underutilize GCT compared to White women. This study will conduct a RCT to test the efficacy of a culturally-tailored theory-based video intervention aimed to address key psychosocial factors …
- 0 views
- 19 Feb, 2024
Assessing the Sensitivity of "SureTouch " in Identifying Clinically Significant Masses in Women Undergoing Diagnostic and Screening Mammography
Prospective, case-control study being conducted to determine the sensitivity of the SureTouch device in detecting known masses at a pre-determined level of specificity.
- 0 views
- 19 Feb, 2024
Personalized Second Chance Breast Conservation (PSCBC): A Two Center Prospective Phase II Clinical Study
The goal of the study is to investigate the feasibility of enabling a second chance for breast conservation in patients with in-breast recurrences after a previous lumpectomy and RT, investigators propose to test partial breast irradiation with the target volume encompassing the entire surgical bed with 1.0-1.5 cm margins.
- 0 views
- 19 Feb, 2024
HER2-PREDICT: Translational Study of Tumor Samples From DS8201-A-U301 and DS8201-A-U302 Trials.
This is a multi-center, observational study. Patients who will participate, are participating or have participated in Daichi Sankyo INC sponsored Ds8201-A-U301 and Ds8201-A-U302 trials will be asked to participate to HER2-PREDICT study offering them a new informed consent. In order to identify mRNA ERBB2 levels, we will evaluate by gene …
- 0 views
- 19 Feb, 2024
Carbon-Fibre Accessory (CARA) for Supine Breast Positioning to Reduce Toxicity in Whole Breast Radiotherapy
This trial is designed to assess the efficacy of a novel carbon-fibre adjustable reusable accessory (CARA) for breast support to reduce skin toxicity and unwanted normal tissue dose in comparison to the current clinical standard for supine breast support during whole breast RT.
- 0 views
- 19 Feb, 2024
An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC.
This is a Phase II, open-label, randomized controlled umbrella trial evaluating the efficacy and safety of multiple targeted treatment in patients with metastaticTNBC.
- 0 views
- 19 Feb, 2024
A Study to Evaluate the Efficacy and Safety of the Combination of TQ-B211 Plus Docetaxel in Patients With HER2-positive MBC.
To evaluate the efficacy,safety and immunogenicity of TQ-B211 plus docetaxel versus Herceptin plus docetaxel in Patients with HER2-positive metastatic breast cancer.Trastuzumab plus docetaxel was chosen as the comparator in the control group,as it represents a common first-line treatment option used in HER2+ MBC population in China.
- 0 views
- 19 Feb, 2024